A Phase 3 interventional study of ezetimibe 10 mg and atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 2nd largest by enrollment of the 97 interventional ones that give a count, is the only one that started in 2010, is one of 50 in phase 3, and was the 63rd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,547 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 5th largest by enrollment of the 81 interventional ones that give a count, is the only one that started in 2010, is one of 58 in phase 3, and was the 74th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare the lipid-altering efficacy and safety of switching to co-administration of ezetimibe and atorvastatin versus treatment with atorvastatin or rosuvastatin in high cardiovascular risk patients with hypercholesterolemia who have not achieved specified low-density lipoprotein cholesterol (LDL-C) levels. The primary hypothesis is that the co-administration of ezetimibe 10 mg and atorvastatin 10 mg will be superior to both atorvastatin 20 mg and rosuvastatin 10 mg with respect to the percentage reduction in low-density lipoprotein-cholesterol (LDL-C) after 6 weeks of treatment.
This is a 18 week randomized, double-blind, active-controlled, multicenter study composed of a 6 week screening/run-in and 12 week double-blind treatment period (composed of 2 phases; each 6 weeks in duration). Only those participants who do not meet low density lipoprotein-cholesterol (LDL-C) goals at the end of Phase I (Week 6), were eligible to continue into Phase II (Week 12).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Co-administration of EZ 10 mg tablet + Atorva 10 mg tablet; once daily for 6 weeks
Drug: ezetimibe 10 mg · Drug: atorvastatin
Atorvastatin 20 mg tablet once daily for 6 weeks
Drug: atorvastatin
Rosuvastatin 10 mg tablet once daily for 6 weeks
Drug: Comparator: rosuvastatin
Participants who had previously received EZ 10 mg + Atorva 10 mg in Phase I and continued on EZ 10 mg + Atorva 10 mg once daily for 6 weeks during Phase II regardless of whether or not LDL-C goals were achieved in Phase I
Drug: ezetimibe 10 mg · Drug: atorvastatin
Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched to EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
Drug: ezetimibe 10 mg · Drug: atorvastatin
Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched Atorva 40 mg once daily for 6 weeks in Phase II
Drug: atorvastatin
Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and received EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
Drug: ezetimibe 10 mg · Drug: atorvastatin
Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and were switched to Rosuvastatin 20 mg once daily for 6 weeks in Phase
Drug: Comparator: rosuvastatin
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)
LDL-C levels measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. LDL-C was calculated using the Friedewald method when triglyceride (TG)\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG≥350 mg/dL (3.95 mmol/L).
Time frame: Baseline and Week 6 (end of Phase I )
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase II).
LDL-C levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12). Baseline was defined as the average of the values at Visits 5 and 6. LDL-C was calculated using the Friedewald method when triglyceride (TG)\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG ≥350 mg/dL (3.95 mmol/L).
Time frame: Baseline (Week 6) and Week 12
Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase I)
Time frame: Week 6 (End of Phase I)
Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase II)
Time frame: Week 12 (End of Phase II)
Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase I)
Time frame: Week 6 (End of Phase I)
Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase II)
Time frame: Week 12 (end of Phase II)
Percent Change From Baseline in Total Cholesterol (TC) (Phase I)
TC measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
Time frame: Baseline and Week 6 (end of Phase I)
Percent Change From Baseline in Total Cholesterol (TC) (Phase II)
TC levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
Time frame: Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)
Percent Change From Baseline in Triglycerides (TG) (Phase I)
TG measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.
Time frame: Baseline and Week 6 (end of Phase I)
Percent Change From Baseline in Triglycerides (TG) (Phase II)
TG levels measured at Baseline (Week 6: end of Phase I) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.
Time frame: Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)
Percent Change From Baseline in High-density Lipoprotein-Cholesterol (HDL-C) (Phase I)
HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
Time frame: Baseline and Week 6 (end of Phase I)
Percent Change From Baseline in HDL-C (Phase II)
HDL-C levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
Time frame: Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)
Percent Change From Baseline in Apolipoprotein B (Apo B) (Phase I)
Apo-B measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
Time frame: Baseline and Week 6 (end of Phase I)
Percent Change From Baseline in Apo B (Phase II)
Apo-B levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) (Phase I)
Apo-A-I measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
Time frame: Baseline and Week 6 (end of Phase I)
Percent Change From Baseline in Apo A-I (Phase II)
Apo-A-I levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
Time frame: Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)
Percent Change From Baseline in Non-HDL-C (Phase I)
Non-HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
Time frame: Baseline and Week 6 (end of Phase I)
Percent Change From Baseline in Non-HDL-C (Phase II)
Non-HDL-C levels calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
Time frame: Baseline (Week 6; end of Phase I) and Week 12 (end of Phase II)
Percent Change From Baseline in TC/HDL-C Ratio (Phase I)
TC/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
Time frame: Baseline and Week 6 (end of Phase I)
Percent Change From Baseline in TC/HDL-C Ratio (Phase II)
TC/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase I)
LDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
Time frame: Baseline and Week 6 (end of Phase I)
Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase II)
LDL-C/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase I)
Apo B/Apo A-I ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
Time frame: Baseline and Week 6 (end of Phase I)
Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase II)
Apo B/Apo A-I Ratio calculated at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase I)
Non HDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
Time frame: Baseline and Week 6 (end of Phase I)
Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase II)
Non HDL-C/HDL-C Ratio calculated at baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) (Phase I)
hs-CRP measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.
Time frame: Baseline and Week 6 (end of Phase I)
Percent Change From Baseline in Hs-CRP (Phase II)
hs-CRP measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.
Time frame: Baseline (Week 6; end of Phase 1) and Week 12 (end of Phase II)
| Milestone | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Phase I: Rosuvastatin 10 mg | Phase II: EZ 10mg+Atorva 10mg | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg |
|---|---|---|---|---|---|---|---|---|
| Started | 120 | 483 | 944 | 0 | 0 | 0 | 0 | 0 |
| Completed | 117 | 455 | 888 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 28 | 56 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 6 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 3 | 9 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 10 | 29 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 11 | 12 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Phase I: Rosuvastatin 10 mg | Phase II: EZ 10mg+Atorva 10mg | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 28 | 124 | 126 | 234 | 206 |
| Completed | 0 | 0 | 0 | 27 | 116 | 121 | 225 | 200 |
| Not completed | 0 | 0 | 0 | 1 | 8 | 5 | 9 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 2 | 0 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 4 | 2 | 5 | 4 |
LDL-C levels measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. LDL-C was calculated using the Friedewald method when triglyceride (TG)\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG≥350 mg/dL (3.95 mmol/L).
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Phase I: Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I) | -24.8 ± 23.6 | -10.1 ± 20.8 | -13.8 ± 22.8 |
LDL-C levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12). Baseline was defined as the average of the values at Visits 5 and 6. LDL-C was calculated using the Friedewald method when triglyceride (TG)\<350 mg/dL (3.95 mmol/L) and beta quantification ultracentrifugation when TG ≥350 mg/dL (3.95 mmol/L).
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase II). | -16.4 ± 31.1 | -8.1 ± 23.3 | -19.3 ± 32.1 | -8.4 ± 20.8 | 2.4 ± 27.4 |
| Percentage of Participants | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Rosuvastatin 10 mg |
|---|---|---|---|
| Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase I) | 56.3 ± 4.55 | 37.4 ± 2.23 | 43.6 ± 1.64 |
| Percentage of Participants | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase II) | 55.8 ± 4.53 | 34.1 ± 4.28 | 53.5 ± 3.30 | 35.8 ± 3.38 | NA |
| Percentage of Participants | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Rosuvastatin 10 mg |
|---|---|---|---|
| Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase I) | 19.3 ± 3.62 | 3.0 ± 0.78 | 6.6 ± 0.82 |
| Percentage of Participants | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase II) | 18.3 ± 3.53 | 0.8 ± 0.81 | 15.4 ± 2.39 | 3.0 ± 1.20 | NA |
TC measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC) (Phase I) | -13.6 ± 17.0 | -6.3 ± 14.1 | -8.2 ± 14.7 |
TC levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC) (Phase II) | -10.2 ± 19.9 | -2.9 ± 15.7 | -13.1 ± 22.8 | -5.0 ± 14.0 | 2.2 ± 15.4 |
TG measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) (Phase I) | -6.0 (-10.9 to -0.8) | -3.9 (-6.5 to -1.2) | -1.1 (-3.1 to 0.9) |
TG levels measured at Baseline (Week 6: end of Phase I) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) (Phase II) | -5.9 (-11.0 to -0.4) | -3.1 (-8.4 to 2.4) | -10.2 (-13.9 to -6.4) | -3.2 (-7.3 to 1.2) | NA (NA to NA) |
HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in High-density Lipoprotein-Cholesterol (HDL-C) (Phase I) | 0.9 ± 11.9 | -1.3 ± 11.6 | 1.0 ± 13.1 |
HDL-C levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in HDL-C (Phase II) | 0.9 ± 14.1 | 1.0 ± 16.0 | -0.8 ± 13.7 | 0.0 ± 15.2 | 0.0 ± 11.7 |
Apo-B measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (Apo B) (Phase I) | -12.1 ± 20.7 | -6.1 ± 20.7 | -7.6 ± 20.1 |
Apo-B levels measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Apo B (Phase II) | -12.0 ± 26.5 | -6.3 ± 19.6 | -14.0 ± 25.1 | -4.9 ± 21.8 | -4.0 ± 16.8 |
Apo-A-I measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) (Phase I) | -0.6 ± 13.1 | -1.9 ± 12.5 | 1.4 ± 13.0 |
Apo-A-I levels measured at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Apo A-I (Phase II) | 1.6 ± 11.9 | 1.4 ± 14.1 | -0.6 ± 14.4 | 0.0 ± 16.0 | -0.7 ± 14.3 |
Non-HDL-C measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C (Phase I) | -18.0 ± 22.3 | -7.9 ± 17.6 | -11.1 ± 19.8 |
Non-HDL-C levels calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C (Phase II) | -17.5 ± 26.1 | -5.5 ± 16.6 | -18.1 ± 29.4 | -6.3 ± 18.5 | -0.5 ± 17.7 |
TC/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in TC/HDL-C Ratio (Phase I) | -14.3 ± 17.9 | -4.5 ± 16.8 | -9.0 ± 19.1 |
TC/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in TC/HDL-C Ratio (Phase II) | -13.5 ± 21.7 | -6.5 ± 13.9 | -11.7 ± 23.3 | -4.0 ± 17.8 | -1.0 ± 9.6 |
LDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Phase 1: Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase I) | -23.9 ± 23.6 | -7.1 ± 23.2 | -14.7 ± 26.9 |
LDL-C/HDL-C Ratio calculated at Baseline (end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase II) | -20.6 ± 31.4 | -8.2 ± 20.6 | -18.2 ± 31.6 | -7.5 ± 21.5 | -4.5 ± 22.9 |
Apo B/Apo A-I ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Phase 1: Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase I) | -13.0 ± 22.3 | -4.8 ± 18.9 | -8.8 ± 23.0 |
Apo B/Apo A-I Ratio calculated at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase II) | -11.2 ± 26.2 | -6.4 ± 19.4 | -11.2 ± 27.5 | -5.4 ± 21.5 | -6.7 ± 11.3 |
Non HDL-C/HDL-C ratio calculated at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Phase 1: Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase I) | -18.9 ± 23.9 | -6.3 ± 22.8 | -12.2 ± 25.9 |
Non HDL-C/HDL-C Ratio calculated at baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6.
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase II) | -18.2 ± 29.5 | -8.8 ± 18.8 | -16.3 ± 32.3 | -5.9 ± 23.4 | -1.9 ± 12.9 |
hs-CRP measured at Baseline and after 6 weeks of treatment (Week 6; end of Phase I). Baseline was defined as the average value of the measurements taken at Visits 3 and 4. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.
| Percentage Change | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Phase I: Rosuvastatin 10 mg |
|---|---|---|---|
| Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) (Phase I) | -10.5 (-23.0 to 4.0) | -6.6 (-13.6 to 1.0) | -9.0 (-14.0 to -3.6) |
hs-CRP measured at Baseline (Week 6; end of Phase 1) and after 6 weeks of study drug administration (Week 12; end of Phase II). Baseline was defined as the average of the values at Visits 5 and 6. Baseline and post-baseline measurements were log-transformed in the response vector, with fixed effects for treatment, time and the interaction of time by treatment.
| Percentage Change | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg | Phase II: EZ 10mg+Atorva 10mg |
|---|---|---|---|---|---|
| Percent Change From Baseline in Hs-CRP (Phase II) | -19.5 (-31.5 to -5.3) | -6.4 (-20.2 to 9.8) | -10.9 (-20.9 to 0.3) | 0.7 (-11.2 to 14.2) | NA (NA to NA) |
Collected over up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | — | 0/120 (0%) | 0/120 (0%) |
| Phase I: Atorvastatin 20 mg | — | 3/480 (0.6%) | 0/480 (0%) |
| Phase I: Rosuvastatin 10 mg | — | 10/939 (1.1%) | 0/939 (0%) |
| Phase II: EZ 10mg+Atorva 10mg | — | 0/28 (0%) | 0/28 (0%) |
| Phase II: EZ 10mg + Atorva 20mg [A] | — | 2/124 (1.6%) | 0/124 (0%) |
| Phase II: Atorva 40mg | — | 2/124 (1.6%) | 0/124 (0%) |
| Phase II: EZ 10mg + Atorva 20mg [R] | — | 5/231 (2.2%) | 0/231 (0%) |
| Phase II: Rosuvastatin 20mg | — | 1/205 (0.5%) | 0/205 (0%) |
| Event | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Phase I: Rosuvastatin 10 mg | Phase II: EZ 10mg+Atorva 10mg | Phase II: EZ 10mg + Atorva 20mg [A] | Phase II: Atorva 40mg | Phase II: EZ 10mg + Atorva 20mg [R] | Phase II: Rosuvastatin 20mg |
|---|---|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/120 | 0/480 | 1/939 | 0/28 | 0/124 | 1/124 | 0/231 | 0/205 |
| Angina unstableCardiac disorders | 0/120 | 0/480 | 0/939 | 0/28 | 0/124 | 1/124 | 0/231 | 0/205 |
| Vitreous haemorrhageEye disorders | 0/120 | 0/480 | 0/939 | 0/28 | 1/124 | 0/124 | 0/231 | 0/205 |
| Chest painGeneral disorders | 0/120 | 0/480 | 0/939 | 0/28 | 1/124 | 0/124 | 0/231 | 0/205 |
| Cerebral infarctionNervous system disorders | 0/120 | 0/480 | 0/939 | 0/28 | 0/124 | 0/124 | 0/231 | 1/205 |
| Coronary artery diseaseCardiac disorders | 0/120 | 1/480 | 0/939 | 0/28 | 0/124 | 0/124 | 1/231 | 0/205 |
| Angina pectorisCardiac disorders | 0/120 | 0/480 | 0/939 | 0/28 | 0/124 | 0/124 | 1/231 | 0/205 |
| Alcohol poisoningInjury, poisoning and procedural complications | 0/120 | 0/480 | 0/939 | 0/28 | 0/124 | 0/124 | 1/231 | 0/205 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/120 | 0/480 | 0/939 | 0/28 | 0/124 | 0/124 | 1/231 | 0/205 |
| Calculus urinaryRenal and urinary disorders | 0/120 | 0/480 | 0/939 | 0/28 | 0/124 | 0/124 | 1/231 | 0/205 |
| Age, Customized(Participants) | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Phase I: Rosuvastatin 10 mg | Total |
|---|---|---|---|---|
| <20 years | 0 | 0 | 1 | 1 |
| 20 to 29 years | 0 | 4 | 2 | 6 |
| 30 to 39 years | 1 | 13 | 25 | 39 |
| 40 to 49 years | 16 | 50 | 99 | 165 |
| 50 to 59 years | 37 | 170 | 324 | 531 |
| 60 to 64 years | 27 | 87 | 183 | 297 |
| ≥65 years | 39 | 159 | 310 | 508 |
| Sex: Female, Male(Participants) | Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg | Phase I: Atorvastatin 20 mg | Phase I: Rosuvastatin 10 mg | Total |
|---|---|---|---|---|
| Female | 71 | 253 | 489 | 813 |
| Male | 49 | 230 | 455 | 734 |
No study locations are listed for this record.
The record gives a start of Jul 2010, a primary completion of Sep 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Atorvastatin